GlassScriptPhysician profile
Connor W Evins
NPI 1699359604
$3,187.23
in general payments reported to CMS, 2019-2025
28 companies · $2,448 in 2025
The $2,448 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.59 · 2024: $721 · 2025: $2,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,187.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $438.44 | 2024-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $409.56 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $359.82 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $252.00 | 2024-2025 | |
| Lilly USA, LLC | $215.36 | 2025 | Zepbound, Mounjaro, Kisunla |
| Glaxosmithkline, LLC. | $211.77 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Phathom Pharmaceuticals, INC. | $180.03 | 2024-2025 | Voquezna |
| Pfizer INC. | $156.81 | 2024-2025 | |
| Ardelyx, INC. | $146.21 | 2025 | Ibsrela |
| Advanced Bionics, LLC | $126.85 | 2025 | Hires Ultra Ci Hifocus Ms Electrode |
| Astellas Pharma US INC | $119.02 | 2025 | Veozah |
| Insulet Corporation | $101.20 | 2024-2025 | Omnipod |
| Verona Pharma, INC. | $74.04 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.08 | 2024-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $38.21 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.66 | 2023-2024 | Lifevest |
| Shield Therapeutics INC | $31.66 | 2025 | |
| Exact Sciences Corporation | $30.30 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Inspire Medical Systems, INC. | $25.66 | 2025 | Inspire |
| Eisai INC. | $24.71 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.81 | 2025 | Xifaxan |
| Dynavax Technologies Corporation | $20.99 | 2024 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $19.51 | 2024 | Xarelto |
| Daiichi Sankyo INC. | $18.65 | 2025 | Injectafer |
| Xeris Pharmaceuticals, INC. | $17.00 | 2024 | Gvoke Hypopen |
| Amgen INC. | $16.87 | 2024 | Otezla, Repatha |
| Tactile Systems Technology INC | $16.37 | 2024 | Entre Plus, Flexitouch Plus |
| Esperion Therapeutics, INC. | $13.64 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connor Evins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.